|New Threads Only:|
|New Threads & Replies:|
Forum List » Value Ideas and Strategies|
Share and discuss value investing ideas and investing strategies.
Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX
Posted by: GuruFocus (IP Logged)
Date: January 27, 2013 01:09PM
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below:
CVR Refining LP (CVRR): CEO and President John J. Lipinski Bought 200,000 Shares
CEO and President of CVR Refining LP (CVRR) John J Lipinski bought 200,000 shares on 01/17/2013 at an average price of $25 with a P/S ratio of 0.5095.
CFO and Treasurer Susan M. Ball bought 8,000 shares of CVRR stock on 01/17/2013 at the average price of $25. Susan M. Ball owns at least 8,000 shares after this. Other insiders have also increased their positions in the company.
Huntington Bancshares Inc (HBAN): President, CEO and Chairman Stephen D. Steinour Bought 40,000 Shares
President, CEO and Chairman of Huntington Bancshares Inc (HBAN) Stephen D. Steinour bought 40,000 shares on 01/23/2013 at an average price of $6.93. Huntington Bancshares Inc. was organized under Maryland law in 1966 and headquartered in Columbus, Ohio. Huntington Bancshares Inc has a market cap of $5.9 billion; its shares were traded at around $6.93 with a P/E ratio of 10.5 and P/S ratio of 2.2. The dividend yield of Huntington Bancshares Inc. stocks is 2.3%.
Huntington recently reported 2012 full-year net income of $641 million, an increase of $98.4 million, or 18%, from the prior year. 2012 fourth quarter net income of $167.3 million was essentially unchanged from the prior quarter. Earnings per common share for the year and current quarter were $0.71 and $0.19, respectively, up $0.12 and unchanged from the prior periods.
Ray Dalio owns 45,031 shares as of 09/30/2012, an increase of 135.38% from the previous quarter. This position accounts for 0.0042% of the $7.44 billion portfolio of Bridgewater Associates. Arnold Schneider owns 3,699,835 shares as of 09/30/2012, which accounts for 2.3% of the $1.09 billion portfolio of Schneider Capital Management.
CFO and Sr. Executive Vice President Donald R. Kimble bought 5,000 shares of HBAN stock on 08/15/2012 at the average price of 6.41. Donald R. Kimble owns at least 272,610 shares after this. The price of the stock has increased by 8.11% since. There are mixed trades from other insiders.
ValueVision Media Inc. (VVTV): CEO Keith R. Stewart Bought 100,000 Shares
CEO of ValueVision Media, Inc. (VVTV) Keith R Stewart bought 100,000 shares on 01/18/2013 at an average price of $2.61. ValueVision Media, Inc. was incorporated on June 25, 1990. Valuevision Media, Inc. has a market cap of $127.6 million; its shares were traded at around $2.61 with and P/S ratio of 0.2.
Executive Vice President and CFO William J. Mcgrath bought 10,000 shares of VVTV stock on 12/03/2012 at the average price of 1.79. William J. Mcgrath owns at least 106,680 shares after this. The price of the stock has increased by 45.81% since. Other insiders have also increased their positions in the company.
SunCoke Energy Partners LP (SXCP): Chairman and CEO Frederick A. Henderson Bought 12,000 Shares
Chairman and CEO of SunCoke Energy Partners LP (SXCP) Frederick A. Henderson bought 12,000 shares on 01/18/2013 at an average price of $0. with and P/S ratio of 0.8687.
SunCoke recently reported its fourth quarter preliminary results. Total U.S. coke production is expected to be nearly 1.1 million tons in fourth quarter 2012, up an estimated 67 thousand tons versus fourth quarter 2011. Full year 2012 U.S. coke production is expected to be more than 4.3 million tons, up an estimated 580 thousand tons versus 2011.
Senior Vice President and CFO Mark Newman bought 4,200 shares of SXCP stock on 01/18/2013 at the average price of 19. Mark Newman owns at least 4,200 shares after this.
Progenics Pharmaceuticals, Inc. (PGNX): CEO Mark Robert Baker Bought 1,215 Shares
CEO of Progenics Pharmaceuticals, Inc. (PGNX) Mark Robert Baker bought 1,215 shares on 01/22/2013 at an average price of $2.91. Progenics Pharmaceuticals Inc. or Progenics, is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Progenics Pharmaceuticals, Inc. has a market cap of $98 million; its shares were traded at around $2.91 with and P/S ratio of 13.2.
PGNX recently reported its third quarter 2012 financial results. Net loss for the third quarter of 2012 was $11.3 million or $0.33 basic and diluted per share, compared to net loss of $11.4 million or $0.34 per share in the 2011 period. Net loss for the nine months ended Sept. 30, 2012 was$35.1 million or $1.04 basic and diluted per share, compared to net income of $21.1 million or $0.63 per share in 2011.
For the complete list of stocks that bought by their company CEOs, go to: http://www.gurufocus.com/InsiderBuy.php?position=ceo
Guru Discussed: Arnold Schneider: Current Portfolio, Stock Picks
Stocks Discussed: CVRR, HBAN, VVTV, SXCP, PGNX,
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.